ArticleFrontiers in cardiovascular medicine2025
Blood urea nitrogen to serum albumin ratio as a prognostic marker for 28-day mortality in atrial fibrillation: a retrospective cohort study.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Relationship Between Blood Urea Nitrogen to Albumin Ratio (BAR) and Diabetic Foot Ulcer (DFU) in Diabetic Patients.Healthcare (Basel, Switzerland) · 2026Article
- Lactate-to-albumin ratio and 28 day mortality in hypertensive patients with atrial fibrillation: a retrospective cohort study.European journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The blood urea nitrogen to serum albumin ratio (BAR) has emerged as a potential prognostic marker. This study investigated its association with clinical outcomes in patients with atrial fibrillation (AF). Methods: A retrospective cohort analysis was performed using data from the MIMIC-IV 2.2 database, including 4,977 patients diagnosed with AF. The primary outcome was 28-day mortality. Cox proportional hazards models were applied to evaluate the association between BAR and mortality, and restricted cubic spline (RCS) analysis was used to explore potential non-linear relationships. Results: Of the 4,977 patients analyzed, the 28-day mortality rate was 22.99%. Higher BAR levels were significantly associated with increased risk of mortality. Each one-unit increase in BAR was associated with a 2% higher risk of 28-day mortality (HR 1.02, 95% CI 1.01-1.03). Compared with the lowest quartile (Q1), patients in the highest quartile (Q4) had a significantly increased risk (HR 1.78, 95% CI 1.42-2.22). ROC analysis showed an area under the curve (AUC) of 0.65 for BAR in predicting 28-day mortality. Subgroup analyses confirmed the consistency and robustness of these findings across diverse clinical strata. Conclusions: BAR is an independent predictor of 28-day mortality in patients with AF. Higher BAR levels are strongly associated with worse outcomes, underscoring its potential utility as a risk stratification tool in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.